First Financial Bankshares Inc Trims Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Financial Bankshares Inc trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,550 shares of the medical research company’s stock after selling 230 shares during the quarter. First Financial Bankshares Inc’s holdings in Thermo Fisher Scientific were worth $959,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. West Bancorporation Inc. acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $220,000. State of Alaska Department of Revenue lifted its position in Thermo Fisher Scientific by 6.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 44,387 shares of the medical research company’s stock worth $27,456,000 after acquiring an additional 2,870 shares during the period. Carret Asset Management LLC grew its stake in shares of Thermo Fisher Scientific by 2.3% in the 3rd quarter. Carret Asset Management LLC now owns 7,965 shares of the medical research company’s stock valued at $4,927,000 after purchasing an additional 178 shares during the last quarter. Valley National Advisers Inc. increased its holdings in shares of Thermo Fisher Scientific by 2,392.1% in the third quarter. Valley National Advisers Inc. now owns 2,841 shares of the medical research company’s stock valued at $1,756,000 after purchasing an additional 2,727 shares during the period. Finally, Financial Management Professionals Inc. lifted its holdings in shares of Thermo Fisher Scientific by 40.9% during the third quarter. Financial Management Professionals Inc. now owns 293 shares of the medical research company’s stock worth $181,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Redburn Atlantic started coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective on the stock. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research note on Thursday. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Finally, Bernstein Bank raised their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $649.33.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.5 %

Shares of NYSE:TMO opened at $554.38 on Monday. The company has a market capitalization of $211.77 billion, a P/E ratio of 34.76, a P/E/G ratio of 3.66 and a beta of 0.77. The stock’s fifty day simple moving average is $605.12 and its 200-day simple moving average is $584.07. Thermo Fisher Scientific Inc. has a 52-week low of $420.21 and a 52-week high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the firm posted $5.69 earnings per share. The company’s quarterly revenue was up .2% compared to the same quarter last year. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.